Project Grant HT94252410411
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$405K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Sunnyvale, CA 94089, USA
Similar Awards
This $405,000 Project Grant, awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports Panorama Research Inc.'s development of novel immunotherapies targeting dual cancer-specific antigens for the treatment of advanced ovarian cancer. The award provides funding over a 2-year period from June 1, 2025 to May 31, 2027 to advance Panorama's research on switchable split superantigen fused with antibodies as a safe and controlled immune booster...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The U.S. Department of Defense, through its Military Medical Research and Development program (CFDA 12.420), awarded a $1,290,499 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to enhance the antitumor activity of natural killer cells in ovarian cancer. The 4-year grant, which commenced on September 1, 2024, will support innovative research aimed at developing novel approaches to understanding, detecting, and treating various types of cancer, including ovarian cancer. DFCI, a...
This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The University of Southern California will receive $413,750 through September 2025 under a Project Grant from the Defense Health Agency to develop next-generation chimeric antigen receptor T cells targeting folate receptor 1 for the treatment of ovarian cancer. Funded through the Military Medical Research and Development program (CFDA 12.420), this award will support the grantee's applied medical research efforts to investigate innovative solutions for battlefield health care and transform...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The federal Project Grant award titled "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER" was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $954,000 award to the Massachusetts Institute of Technology (MIT) is focused on developing tumor-targeted nanocarriers for immunomodulation of ovarian cancer. The 3-year project, running from May 2025 to April 2028, aims to advance...
The Department of the Army Medical Command awarded a $1,347,700 Project Grant to Sloan-Kettering Institute For Cancer Research under the Military Medical Research and Development program (CFDA 12.420). The grant will support development of an implantable nanosensor for early-stage ovarian cancer detection from June 2022 through June 2025. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award...